Cyclooxygenase-2 and antagonists in pain management

Current Opinion in Anaesthesiology

Volumn 14, Issue 5, 2001, Pages 527-532

  Samad, Tarek ^a   Abdi, Salahadin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ALZHEIMER DISEASE; ANALGESIA; ANALGESIC ACTIVITY; CARDIOVASCULAR DISEASE; COLON CANCER; COLON POLYP; DRUG DISTRIBUTION; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DISEASE; PAIN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ANOMALY;

EID: 0034796831     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200110000-00011     Document Type: Review

References (61)

1. Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology
2. Cyclooxygenases: Structural, cellular, and molecular biology
3. The cyclooxygenase isoforms: Structural insights into the conversion of arachidonic acid to prostaglandins
4. 2-induced pain responses by use of EP1 and EP3 receptor knockout mice
5. Prostanoid receptors: Structures, properties, and functions
6. Distribution and function of prostanoid receptors: Studies from knockout mice
7. Prostanoid receptors: Subtypes and signaling
8. Cox-2-specific inhibitors: Definition of a new therapeutic concept
9. TIS10, a mitogen-inducible glucocorticoid-inhibited gene that encodes a second prostaglandin synthase/cyclooxygenase enzyme
10. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
11. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
12. Regulated formation of eicosanoids
13. Prostaglandins and inflammation: The cyclooxygenase controversy
14. Persistent accumulation of cyclooxygenase-1 (COX-1) expressing microglia/macrophages and upregulation by endothelium following spinal cord injury
15. Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer
16. Upregulation of cyclooxygenase-1 and the PGE2 receptor EP2 in rat and human mesangioproliferative glomerulonephritis
17. Cyclooxygenase-2: Its rich diversity of roles and possible application of its selective inhibitors
18. Prostaglandins and cycloxygenases in the spinal cord
19. Inflammation and the mechanism of action of anti-inflammatory drugs
20. Towards a better aspirin
21. Tetrodotoxin-resistant Na+ currents and inflammatory hyperalgesia
22. A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat
23. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition
24. 2 and amino acids evoked by paw formalin injection: A microdialysis study in unanesthetized rats
25. 2 release
26. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats
27. Mechanism of action of nonsteroidal anti-inflammatory drugs
28. 2 in the brain
29. 2
30. Cyclooxygenases in the central nervous system: Implications for treatment of neurological disorders
31. COX-2 in brain and spinal cord implications for therapeutic use
32. Spinal systems and pain processing: Development of novel analgesic drugs with mechanistically defined models
33. Spinal systems and pain processing: Development of novel analgesic drugs with mechanistically defined models
34. In vitro prostanoid release from spinal cord following peripheral inflammation: Effects of substance P, NMDA and capsaicin
35. Immunology. Telling the brain about pain
36. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity
37. Cox-2-selective inhibitors: The new super aspirins
38. COX-2-specific inhibitors - The emergence of a new class of analgesic and anti-inflammatory drugs
39. Efficacy of cyclooxygenase-2-specific inhibitors
40. Cyclooxygenaae-2: A major therapeutic advance?
41. Cyclooxygenase-2-specific inhibitors: Are they safe?
42. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery
43. A comparison of the newer COX-2 drugs and older non-narcotic oral analgesics
44. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice
45. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors
46. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
47. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial
48. COX-2 specific inhibitors offer improved advantages over traditional NSAIDs
49. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
50. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain
51. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors
52. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
53. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor
54. Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective
55. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure
56. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition
57. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis
58. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics
59. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem
60. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients
61. Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials